mass cytometry

The company said it saw the biggest revenue growth in its instruments business, which gained 32 percent year over year.

Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.

The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.

Fluidigm reported that its mass cytometry revenues jumped 32 percent while genomics revenues fell 5 percent year over year.

A 30 percent decrease in instrument revenue was tempered by a 23 percent uptick in consumables revenue.

Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.

At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.

Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.

The company gains global distribution rights for the Zurich team's histoCAT cytometry imaging software, which it will sell alongside its newly-launched Hyperion Imaging System.